Raras
Buscar doenças, sintomas, genes...
Hiperaldosteronismo familiar
ORPHA:235936DOENÇA RARA

O Hiperaldosteronismo Familiar (HF) é a forma herdada de hiperaldosteronismo primário (HP), que inclui, até agora, três subtipos identificados: O HF tipo I (HF-I) é caracterizado por pressão alta (hipertensão) que começa cedo, um excesso de aldosterona que melhora com glicocorticoides e depende do hormônio ACTH (adrenocorticotrófico), níveis variáveis de potássio baixo (hipocalemia), e produção excessiva de 18-oxocortisol e 18-hidroxicortisol. O HF tipo II (HF-II) é caracterizado por pressão alta (hipertensão) com gravidade variável e um excesso de aldosterona que não diminui com dexametasona. E o HF tipo III (HF-III) é caracterizado por nível muito baixo de potássio (hipocalemia profunda), pressão alta grave que começa cedo (hipertensão grave de início precoce), excesso de aldosterona que não melhora com glicocorticoides, e produção excessiva de 18-oxocortisol e 18-hidroxicortisol.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

O Hiperaldosteronismo Familiar (HF) é a forma herdada de hiperaldosteronismo primário (HP), que inclui, até agora, três subtipos identificados: O HF tipo I (HF-I) é caracterizado por pressão alta (hipertensão) que começa cedo, um excesso de aldosterona que melhora com glicocorticoides e depende do hormônio ACTH (adrenocorticotrófico), níveis variáveis de potássio baixo (hipocalemia), e produção excessiva de 18-oxocortisol e 18-hidroxicortisol. O HF tipo II (HF-II) é caracterizado por pressão alta (hipertensão) com gravidade variável e um excesso de aldosterona que não diminui com dexametasona. E o HF tipo III (HF-III) é caracterizado por nível muito baixo de potássio (hipocalemia profunda), pressão alta grave que começa cedo (hipertensão grave de início precoce), excesso de aldosterona que não melhora com glicocorticoides, e produção excessiva de 18-oxocortisol e 18-hidroxicortisol.

Publicações científicas
190 artigos
Último publicado: 2026 Mar 6

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
14 sintomas
🫘
Rins
6 sintomas
❤️
Coração
5 sintomas
🦴
Ossos e articulações
2 sintomas
👂
Ouvidos
1 sintomas
💪
Músculos
1 sintomas

+ 18 sintomas em outras categorias

Características mais comuns

Hemorragia intracraniana
Zumbido
Epistaxe
Adenoma adrenocortical secretor
Polidipsia
Paralisia cerebral
49sintomas
Sem dados (49)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 49 características clínicas mais associadas, ordenadas por frequência.

Hemorragia intracranianaIntracranial hemorrhage
ZumbidoTinnitus
EpistaxeEpistaxis
Adenoma adrenocortical secretorSecretory adrenocortical adenoma
PolidipsiaPolydipsia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico190PubMed
Últimos 10 anos107publicações
Pico202313 papers
Linha do tempo
2026Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

CACNA1DVoltage-dependent L-type calcium channel subunit alpha-1DDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkyla

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (4)
NCAM1 interactionsRegulation of insulin secretionAdrenaline,noradrenaline inhibits insulin secretionSensory processing of sound by inner hair cells of the cochlea
MECANISMO DE DOENÇA

Sinoatrial node dysfunction and deafness

A disease characterized by congenital severe to profound deafness without vestibular dysfunction, associated with episodic syncope due to intermittent pronounced bradycardia.

OUTRAS DOENÇAS (2)
aldosterone-producing adenoma with seizures and neurological abnormalitiessinoatrial node dysfunction and deafness
HGNC:1391UniProt:Q01668
CYP11B2Cytochrome P450 11B2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure (PubMed:11856349, PubMed:12530636, PubMed:1518866, PubMed:15356073, PubMed:1594605, PubMed:1775135, PubMed:22446688, PubMed:23322723, PubMed:9814482, PubMed:9814506). Catalyzes three sequential oxidative reactions of 11-deoxyco

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Endogenous sterolsGlucocorticoid biosynthesisMineralocorticoid biosynthesis
MECANISMO DE DOENÇA

Corticosterone methyloxidase 1 deficiency

Autosomal recessive disorder of aldosterone biosynthesis. There are two biochemically different forms of selective aldosterone deficiency be termed corticosterone methyloxidase (CMO) deficiency type 1 and type 2. In CMO-1 deficiency, aldosterone is undetectable in plasma, while its immediate precursor, 18-hydroxycorticosterone, is low or normal.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula adrenal
89.4 TPM
Testículo
0.2 TPM
Cervix Ectocervix
0.0 TPM
Baço
0.0 TPM
Fígado
0.0 TPM
OUTRAS DOENÇAS (4)
corticosterone methyloxidase type 1 deficiencycorticosterone methyloxidase type 2 deficiencyglucocorticoid-remediable aldosteronismearly-onset familial hypoaldosteronism
HGNC:2592UniProt:P19099
CYP11B1Cytochrome P450 11B1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

A cytochrome P450 monooxygenase involved in the biosynthesis of adrenal corticoids (PubMed:12530636, PubMed:1518866, PubMed:1775135, PubMed:18215163, PubMed:23322723). Catalyzes a variety of reactions that are essential for many species, including detoxification, defense, and the formation of endogenous chemicals like steroid hormones. Steroid 11beta, 18- and 19-hydroxylase with preferred regioselectivity at 11beta, then 18, and lastly 19 (By similarity). Catalyzes the hydroxylation of 11-deoxyc

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Endogenous sterolsGlucocorticoid biosynthesis
MECANISMO DE DOENÇA

Adrenal hyperplasia 4

A form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late-onset (NC or LOAH) and 'cryptic' (asymptomatic).

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula adrenal
4787.3 TPM
Testículo
6.4 TPM
Cervix Ectocervix
0.9 TPM
Fallopian Tube
0.5 TPM
Bladder
0.5 TPM
OUTRAS DOENÇAS (2)
glucocorticoid-remediable aldosteronismcongenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency
HGNC:2591UniProt:P15538
CACNA1HVoltage-dependent T-type calcium channel subunit alpha-1HDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Voltage-sensitive calcium channel that gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group. A particularity of this type of channel is an opening at quite negative potentials, and a voltage-dependent inactivation (PubMed:27149520, PubMed:9670923, PubMed:9930755). T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle (Probabl

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
NCAM1 interactionsSmooth Muscle ContractionMechanical load activates signaling by PIEZO1 and integrins in osteocytes
MECANISMO DE DOENÇA

Epilepsy, idiopathic generalized 6

A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.

OUTRAS DOENÇAS (3)
hyperaldosteronism, familial, type IVchildhood absence epilepsyepilepsy, childhood absence, susceptibility to, 6
HGNC:1395UniProt:O95180
CLCN2Chloride channel protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Voltage-gated and osmosensitive chloride channel. Forms a homodimeric channel where each subunit has its own ion conduction pathway. Conducts double-barreled currents controlled by two types of gates, two fast glutamate gates that control each subunit independently and a slow common gate that opens and shuts off both subunits simultaneously. Displays inward rectification currents activated upon membrane hyperpolarization and extracellular hypotonicity (PubMed:16155254, PubMed:17567819, PubMed:19

LOCALIZAÇÃO

Cell membraneBasolateral cell membraneCell projection, dendritic spine membraneCell projection, axon

VIAS BIOLÓGICAS (1)
Stimuli-sensing channels
MECANISMO DE DOENÇA

Epilepsy, idiopathic generalized 11

A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.

VIAS REACTOME (1)
OUTRAS DOENÇAS (4)
leukoencephalopathy with mild cerebellar ataxia and white matter edemafamilial hyperaldosteronism type IIjuvenile myoclonic epilepsyepilepsy, idiopathic generalized, susceptibility to, 11
HGNC:2020UniProt:P51788
KCNJ5G protein-activated inward rectifier potassium channel 4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium. This potassium channel is control

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (2)
Activation of G protein gated Potassium channelsInhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
MECANISMO DE DOENÇA

Long QT syndrome 13

A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula adrenal
62.9 TPM
Pituitária
25.4 TPM
Baço
10.2 TPM
Pâncreas
8.2 TPM
Rim - Medula
6.3 TPM
OUTRAS DOENÇAS (5)
familial hyperaldosteronism type IIIlong QT syndrome 13familial atrial fibrillationAndersen-Tawil syndrome
HGNC:6266UniProt:P48544

Variantes genéticas (ClinVar)

831 variantes patogênicas registradas no ClinVar.

🧬 CACNA1D: NM_001128840.3(CACNA1D):c.698G>A (p.Gly233Asp) ()
🧬 CACNA1D: NM_001128840.3(CACNA1D):c.3323A>G (p.Tyr1108Cys) ()
🧬 CACNA1D: NM_001128840.3(CACNA1D):c.881T>G (p.Ile294Ser) ()
🧬 CACNA1D: NM_001128840.3(CACNA1D):c.2241C>G (p.Phe747Leu) ()
🧬 CACNA1D: NM_001128840.3(CACNA1D):c.6029A>G (p.Asp2010Gly) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 331 variantes classificadas pelo ClinVar.

17
314
Patogênica (5.1%)
VUS (94.9%)
VARIANTES MAIS SIGNIFICATIVAS
KCNJ5: NM_000890.5(KCNJ5):c.91G>A (p.Asp31Asn) [Conflicting classifications of pathogenicity]
KCNJ5: NM_000890.5(KCNJ5):c.154C>T (p.Arg52Cys) [Uncertain significance]
CLCN2: NM_004366.6(CLCN2):c.1053G>C (p.Lys351Asn) [Uncertain significance]
KCNJ5: NM_000890.5(KCNJ5):c.1250G>T (p.Gly417Val) [Uncertain significance]
KCNJ5: NM_000890.5(KCNJ5):c.1250G>A (p.Gly417Asp) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Hiperaldosteronismo familiar

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
96 papers (10 anos)
#1

One-stop evaluation using [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT for visualization and localization of adrenal nodules in patients with primary aldosteronism.

Japanese journal of radiology2026 Mar 06

To evaluate the diagnostic utility of integrating [68Ga]Ga-Pentixafor PET with contrast-enhanced CT (CECT) for the visualization and localization of adrenal lesions in patients with primary aldosteronism (PA). Thirty-five patients with clinically suspected PA who underwent [68Ga]Ga-Pentixafor PET and integrated CECT scans were retrospectively enrolled in this study. Adrenal lesions were identified and segmented using non-threshold methods. PET parameters (SUVmax, lesion-to-contralateral adrenal ratio [LCR], lesion-to-liver ratio [LLR]) and CT parameters (attenuation values, absolute and relative washout) were measured, and their correlations were analyzed. Abdominopelvic CT angiography was reconstructed to rule out vasogenic hypertension, and three-dimensional volume reconstruction from CECT data was applied for the visualization and localization of adrenal lesions. Additionally, a logistic regression model with cross-validation was constructed to predict aldosterone-producing adenomas (APA). Among these 35 patients, a total of 56 adrenal lesions including APA (n = 26), idiopathic hyperplasia (IHA, n = 26), nonfunctioning adenomas (NFA, n = 3), and familial hyperaldosteronism (n = 1) were identified and segmented from both [68Ga]Ga-Pentixafor PET and CECT images. APA demonstrated significantly higher SUVmax, LCR, and LLR, as well as lower delayed-phase CT values and greater absolute/relative washout compared with non-APA lesions (P < 0.05). One (1/35) patient exhibited mild renal artery stenosis, while no patients were found to have other renal abnormalities. A multivariable model incorporating SUVmax, relative washout, and diameter of lesions, achieved excellent discrimination between APA and non-APA lesions (area under the curve [AUC] = 0.912), outperforming individual parameters. The integration of [68Ga]Ga-Pentixafor PET with CECT provides a non-invasive, comprehensive diagnostic approach for PA, enhancing lesion detection, subtype classification, and surgical planning, which may be incorporated into clinical practice.

#2

Early-onset hypertension associated with a CACNA1H variant of uncertain significance: a case report and literature review.

BMC cardiovascular disorders2026 Feb 04

The prevalence of early-onset hypertension is rising annually and is accompanied by progressive target organ damage, contributing to a higher risk of cardiovascular mortality. In patients with early-onset hypertension characterized by refractory hypertension, elevated plasma aldosterone levels, and a family history of hypertension, monogenic hereditary hypertension, such as familial hyperaldosteronism, should be suspected, although this condition is rare. A 36-year-old male patient with hypertension fails to achieve target blood pressure despite receiving four antihypertensive medications, including a diuretic. The patient exhibited elevated plasma aldosterone levels, while the aldosterone-to-renin ratio and serum potassium levels remain within normal ranges. Further genetic analysis identifies a heterozygous variant of uncertain significance in the CACNA1H gene (nucleotide change: c.3988G > A, amino acid change: p.V1330I, chromosomal location: chr16:1260601). This genetic variant has not been previously reported. The CACNA1H gene is associated with familial hyperaldosteronism type IV. Sanger sequencing validation and family pedigree analysis were performed, confirming an autosomal dominant inheritance pattern among family members. For patients with early-onset hypertension characterized by refractory hypertension, elevated plasma aldosterone levels, and a family history of hypertension, monogenic forms of hypertension, such as familial hyperaldosteronism, should be suspected. However, For patients with negative ARR but atypical clinical manifestations of elevated aldosterone levels, exclusive reliance on common biochemical markers, such as the aldosterone-to-renin ratio and serum potassium levels, may lead to misdiagnosis or underdiagnosis. Therefore, in addition to routine biochemical markers, genetic testing should be considered a complementary diagnostic tool for patients with early-onset hypertension and a family history of hypertension.

#3

Familial Hyperaldosteronism Type IV in a Mother-Daughter Pair.

American journal of hypertension2026 Feb 01
#4

New mutation of CACNA1H p.Tyr613Phe in hyperaldosteronism: a case report.

Frontiers in medicine2025

Primary aldosteronism (PA) is an endocrine disorder characterized by the autonomous, excessive production of aldosterone from the adrenal glands. Familial hyperaldosteronism (FH) is one type of PA. FH is further subclassified into types I through IV according to different gene mutations. This paper reports a case of unilateral adrenal hyperplasia with germline CACNA1H mutation, p.His515Tyr and p.Tyr613Phe, confirmed by endocrine test, whole exome sequencing and Sanger sequencing 4 years after onset. The variants located within N-terminal close to the first transmembrane domain of the protein that was highly conserved across different species. Polyphen2 and PROVEAN predicted p.Tyr613Phe to be probably damaging and deleterious. These findings broaden the genetic spectrum of PA and offer novel insights into the molecular mechanisms driving excessive aldosterone production. Therefore, genetic sequencing is recommended for PA patients whose etiology remains unclear after standard clinical evaluation.

#5

Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.

Hypertension (Dallas, Tex. : 1979)2025 Nov 20

Mutations in the KCNJ5 (potassium inwardly rectifying channel subfamily J member 5) gene, encoding an inwardly rectifying potassium channel, can drive aldosterone overproduction in a subset of aldosterone-producing adenomas and in familial hyperaldosteronism type III. Our objective was to identify small molecule compounds that specifically antagonize mutant KCNJ5 channels. Virtual screening of over 6 million small molecules identified compounds that putatively bind to KCNJ5 channels. The effect of 108 of these candidates was evaluated in vitro in human adrenocortical cells (HAC15) with inducible expression of wild-type or mutated forms of KCNJ5. Assessment encompassed cell viability, flow cytometry, gene expression, and adrenal steroid quantification via liquid chromatography-tandem mass spectrometry. Compounds antagonizing mutated KCNJ5 function were identified by evaluating their ability to rescue adrenal cell death induced by overexpression of mutant KCNJ5. A spiroquinoline compound, referred to as compound 81 (C81), effectively rescued cell death induced by KCNJ5 L168R in both monolayer and spheroid HAC15 cell cultures. C81 treatment caused a 69% to 85% reduction in CYP11B2 (aldosterone synthase) mRNA levels induced by KCNJ5 L168R, G151R, or T158A expression, compared with untreated cells. C81 also reduced aldosterone secretion by 65% in cells expressing KCNJ5 L168R and decreased 18-oxocortisol and 18-hydroxycortisol production by 78% and 90%, respectively. However, C81 had no significant effect on steroid secretion in cells overexpressing wild-type KCNJ5. C81 shows potential as a small molecule antagonist to specifically target pathological aldosterone secretion in familial hyperaldosteronism type III or KCNJ5-mutated aldosterone-producing adenomas. These findings suggest new avenues for genotype-based primary aldosteronism diagnostics and targeted treatments, contributing to personalized patient care.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC72 artigos no totalmostrando 103

2026

One-stop evaluation using [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT for visualization and localization of adrenal nodules in patients with primary aldosteronism.

Japanese journal of radiology
2026

Early-onset hypertension associated with a CACNA1H variant of uncertain significance: a case report and literature review.

BMC cardiovascular disorders
2025

New mutation of CACNA1H p.Tyr613Phe in hyperaldosteronism: a case report.

Frontiers in medicine
2025

Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.

Hypertension (Dallas, Tex. : 1979)
2026

Familial Hyperaldosteronism Type IV in a Mother-Daughter Pair.

American journal of hypertension
2025

Glucocorticoid Remediable Aldosteronism in a Family with a Strong History of Cerebral Aneurysms and Hypertension.

Prague medical report
2025

[Analysis of a family with familial hyperaldosteronism type Ⅳ due to a mutation in the CACNA1H gene].

Zhonghua yi xue za zhi
2025

Familial hyperaldosteronism as a cause of secondary hypertension: a case report in pediatric age.

Nefrologia
2025

Adrenal causes of endocrine hypertension in childhood or adolescence.

Journal of endocrinological investigation
2025

Decoding Monogenic Hypertension: A Review of Rare Hypertension Disorders.

American journal of hypertension
2024

A Case of Primary Aldosteronism Masquerading as Bartter and Gitelman Syndromes.

Cureus
2024

Genetic testing for familial hyperaldosteronism type 1 in Aotearoa/New Zealand.

Internal medicine journal
2025

Genetic Testing for Primary Aldosteronism in SPAIN: Results From the SPAIN-ALDO Registry and Review of the Literature.

The Journal of clinical endocrinology and metabolism
2024

Monogenic Hypertension Linked to the Renin-Angiotensin-Aldosterone System.

Anatolian journal of cardiology
2024

Report on three cases of familial primary aldosteronism type IV.

Journal of hypertension
2024

KCNJ5 mutations in familial and non-familial primary aldosteronism.

European journal of endocrinology
2024

Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.

European journal of endocrinology
2024

Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.

Frontiers in endocrinology
2023

Efficacy comparison between iliosacral screw fixation of the posterior pelvic ring fracture with the assistance of modified percutaneous three-dimensional printing guide template and conventional fluoroscopy.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2024

What We Know about and What Is New in Primary Aldosteronism.

International journal of molecular sciences
2024

The mechanisms of ferroptosis and its role in atherosclerosis.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2024

Nitrogen vacancy-rich carbon nitride anchored with iron atoms for efficient redox dyshomeostasis under ultrasound actuation.

Biomaterials
2023

[Mechanism of miR-186-5p Regulating PRKAA2 to Promote Ferroptosis 
in Lung Adenocarcinoma Cells].

Zhongguo fei ai za zhi = Chinese journal of lung cancer
2023

All-in-one HN@Cu-MOF nanoparticles with enhanced reactive oxygen species generation and GSH depletion for effective tumor treatment.

Journal of materials chemistry. B
2023

Rewriting DNA in the body lowers cholesterol.

Science (New York, N.Y.)
2023

Therapeutic management of congenital forms of endocrine hypertension.

European journal of endocrinology
2023

CACNA1D Gene Polymorphisms Associate With Increased Blood Pressure and Salt Sensitivity of Blood Pressure in White Individuals.

Hypertension (Dallas, Tex. : 1979)
2023

Pathology and gene mutations of aldosterone-producing lesions.

Endocrine journal
2023

Mechanism of DYRK1a in myocardial ischemia-reperfusion injury by regulating ferroptosis of cardiomyocytes.

The Kaohsiung journal of medical sciences
2023

Relevance of KCNJ5 in Pathologies of Heart Disease.

International journal of molecular sciences
2023

CaV3.2 (CACNA1H) in Primary Aldosteronism.

Handbook of experimental pharmacology
2023

Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.

Hypertension (Dallas, Tex. : 1979)
2023

[Current status and reflections of familial hyperaldosteronism].

Zhonghua nei ke za zhi
2023

Pathophysiologic approach in genetic hypokalemia: An update.

Annales d'endocrinologie
2022

Diagnosis, treatment and genetic analysis of a case of familial aldosteronism type II with WFS1 gene mutation.

Yi chuan = Hereditas
2022

Update on the Genetics of Primary Aldosteronism and Aldosterone-Producing Adenomas.

Current cardiology reports
2022

Pathogenesis of Primary Aldosteronism: Impact on Clinical Outcome.

Frontiers in endocrinology
2022

Familial forms and molecular profile of primary hyperaldosteronism.

Hipertension y riesgo vascular
2021

[Testosterone inhibits human wild-type and chimeric aldosterone synthase activity in vitro].

Revista medica de Chile
2021

Familial Hyperaldosteronism Type 3 with a Rapidly Growing Adrenal Tumor: An In Situ Aldosterone Imaging Study.

Current issues in molecular biology
2022

Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review.

Hypertension (Dallas, Tex. : 1979)
2022

Author Correction: Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation.

Nature communications
2022

Pathophysiology of bilateral hyperaldosteronism.

Current opinion in endocrinology, diabetes, and obesity
2022

Classic and current concepts in adrenal steroidogenesis: a reappraisal.

Archives of endocrinology and metabolism
2022

Genetics of Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)
2021

Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Biomedicines
2021

Progress on Genetic Basis of Primary Aldosteronism.

Biomedicines
2021

Diagnosis and treatment of primary aldosteronism.

The lancet. Diabetes &amp; endocrinology
2022

Monogenic forms of low-renin hypertension: clinical and molecular insights.

Pediatric nephrology (Berlin, Germany)
2021

A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.

Endocrine
2021

Enhanced Ca2+ signaling, mild primary aldosteronism, and hypertension in a familial hyperaldosteronism mouse model (Cacna1hM1560V/+ ).

Proceedings of the National Academy of Sciences of the United States of America
2021

Cushing Syndrome in a Pediatric Patient With a KCNJ5 Variant and Successful Treatment With Low-dose Ketoconazole.

The Journal of clinical endocrinology and metabolism
2021

Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone.

Blood pressure
2021

Familial periodic paralysis associated with a rare KCNJ5 variant that supposed to have incomplete penetrance.

Brain &amp; development
2020

Identification of Somatic Mutations in CLCN2 in Aldosterone-Producing Adenomas.

Journal of the Endocrine Society
2020

Molecular Basis of Primary Aldosteronism and Adrenal Cushing Syndrome.

Journal of the Endocrine Society
2020

Old and new genes in primary aldosteronism.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2020

Somatic CACNA1H Mutation As a Cause of Aldosterone-Producing Adenoma.

Hypertension (Dallas, Tex. : 1979)
2019

Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation.

Nature communications
2019

Genetic causes of primary aldosteronism.

Experimental &amp; molecular medicine
2020

Mosaicism for KCNJ5 Causing Early-Onset Primary Aldosteronism due to Bilateral Adrenocortical Hyperplasia.

American journal of hypertension
2019

Timeline of Advances in Genetics of Primary Aldosteronism.

Experientia supplementum (2012)
2019

CLCN2 clicks with aldosterone-producing adenomas, too!

European journal of endocrinology
2019

A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma.

European journal of endocrinology
2019

Molecular mechanisms in primary aldosteronism.

Journal of molecular endocrinology
2019

Overview of Monogenic or Mendelian Forms of Hypertension.

Frontiers in pediatrics
2019

Adrenalectomy Completely Cured Hypertension in Patients With Familial Hyperaldosteronism Type I Who Had Somatic KCNJ5 Mutation.

The Journal of clinical endocrinology and metabolism
2019

Primary aldosteronism associated with a germline variant in CACNA1H.

BMJ case reports
2019

Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

Current hypertension reports
2018

Family hyperaldosteronism type I: a clinical case and review of literature.

Terapevticheskii arkhiv
2019

Familial hyperaldosteronism type III a novel case and review of literature.

Reviews in endocrine &amp; metabolic disorders
2019

Inherited Forms of Primary Hyperaldosteronism: New Genes, New Phenotypes and Proposition of A New Classification.

Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2018

Genetic aspects of primary hyperaldosteronism.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
2018

Saga of Familial Hyperaldosteronism: Yet a New Channel.

Hypertension (Dallas, Tex. : 1979)
2018

Comparative Genomics and Transcriptome Profiling in Primary Aldosteronism.

International journal of molecular sciences
2018

Hypertension: CLCN2 chloride channel mutations in primary aldosteronism.

Nature reviews. Nephrology
2018

Overview of aldosterone-related genetic syndromes and recent advances.

Current opinion in endocrinology, diabetes, and obesity
2018

CLCN2 chloride channel mutations in familial hyperaldosteronism type II.

Nature genetics
2018

GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism.

European journal of endocrinology
2018

Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway.

Journal of clinical lipidology
2017

Unanswered Questions in the Genetic Basis of Primary Aldosteronism.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2017

ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II).

Journal of human hypertension
2018

DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

European journal of endocrinology
2017

Familial hyperaldosteronism type III.

Journal of human hypertension
2017

Somatic and inherited mutations in primary aldosteronism.

Journal of molecular endocrinology
2016

Evaluation of a Recently Established Test for Familial Hyperaldosteronism Type 1.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2016

A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing's Syndrome.

The Journal of clinical endocrinology and metabolism
2017

Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Molecular and cellular endocrinology
2016

CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism.

EBioMedicine
2016

Genetics of primary hyperaldosteronism.

Endocrine-related cancer
2016

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.

Annales d'endocrinologie
2016

Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion.

Clinical endocrinology
2016

Recent Developments in Primary Aldosteronism.

Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2016

Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production.

Journal of molecular endocrinology
2016

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.

Annales d'endocrinologie
2017

Genetic disorders in primary aldosteronism-familial and somatic.

The Journal of steroid biochemistry and molecular biology
2016

Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension.

Clinical chemistry and laboratory medicine
2015

Bilateral Idiopathic Adrenal Hyperplasia: Genetics and Beyond.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2015

An Update on Familial Hyperaldosteronism.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2016

Hyperplasia in glands with hormone excess.

Endocrine-related cancer
2015

Inherited forms of mineralocorticoid hypertension.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2015

Primary aldosteronism: challenges in diagnosis and management.

Endocrinology and metabolism clinics of North America
2015

The molecular basis of primary aldosteronism: from chimeric gene to channelopathy.

Current opinion in pharmacology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Hiperaldosteronismo familiar.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Hiperaldosteronismo familiar

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. One-stop evaluation using [68Ga]Ga-Pentixafor PET integrated with contrast-enhanced CT for visualization and localization of adrenal nodules in patients with primary aldosteronism.
    Japanese journal of radiology· 2026· PMID 41790412mais citado
  2. Early-onset hypertension associated with a CACNA1H variant of uncertain significance: a case report and literature review.
    BMC cardiovascular disorders· 2026· PMID 41639773mais citado
  3. Familial Hyperaldosteronism Type IV in a Mother-Daughter Pair.
    American journal of hypertension· 2026· PMID 41191643mais citado
  4. New mutation of CACNA1H p.Tyr613Phe in hyperaldosteronism: a case report.
    Frontiers in medicine· 2025· PMID 41601799mais citado
  5. Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels.
    Hypertension (Dallas, Tex. : 1979)· 2025· PMID 41263073mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:235936(Orphanet)
  2. MONDO:0016525(MONDO)
  3. GARD:20630(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1640860(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Hiperaldosteronismo familiar

ORPHA:235936 · MONDO:0016525
Prevalência
Unknown
Herança
Autosomal dominant
Início
All ages
Prevalência
0.0 (Europe)
MedGen
UMLS
C0010481
Repurposing
1 candidato
spironolactonemineralocorticoid receptor antagonist
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades